On February 19, 2026, Candel Therapeutics, Inc. announced an agreement to sell 18,348,624 shares of common stock at $5.45 per share, expecting to raise about $93.5 million for future projects, including a phase 3 trial for CAN-2409. The offering is set to close around February 23, 2026.